Publication
Activating mTOR mutations in a patient with an extraordinary response on a phase I trial of everolimus and pazopanib.
Authors not recorded
- Source
- PubMed
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CIVIC-20260908-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
Data not yet available
Linked entities
Linked entities (8)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Validated 8
- cancerBladder Carcinomacivic_curation1.00
- cancerTransitional Cell Carcinomacivic_curation1.00
- drugEverolimuscivic_curation1.00
- drugPazopanibcivic_curation1.00
- geneMTORcivic_curation1.00
- variantMTOR E2014Kcivic_curation1.00
- variantMTOR E2419Kcivic_curation1.00
- variantMTOR Mutationcivic_curation1.00
Curated evidence
Evidence citing this paper (2)
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 24625776
- Run
- ING-CIVIC-20260908-000001
| Therapy | Cancer | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| MTOR Mutation1 | ||||||||
| Everolimus + PazopanibCombination | Bladder Carcinoma | Predictive | C | Supports Sensitivity Response | 3 | accepted | EID705A case-study of a patient with urothelial carcinoma reported exceptional response (14 months) in a phase 1 study of Everolimus and Pazopanib. Mutations E2014K and E2419K were shown to be activating in… (full text at CIViC) PMID 24625776 · Wagle et al., 2014 · Open in CIViC | civic |
| MTOR E2014K + MTOR E2419K1 | ||||||||
| Everolimus + PazopanibCombination | Transitional Cell Carcinoma | Predictive | C | Supports Sensitivity Response | 2 | accepted | EID1438A phase 1 clinical trial identified a patient with chemotherapy-refractory urothelial carcinoma who had complete radiographic response lasting 14 months after combined everolimus and pazopanib treatme… (full text at CIViC) PMID 24625776 · Wagle et al., 2014 · Open in CIViC | civic |